← Back
Molina Healthcare
MOH · listed on the New York Stock Exchange · worth $10.65 billion
$204.78
−4.32% today
One insider buy in the last year, $100.1K in all. None in the last two weeks. One member of Congress reported trading Molina Healthcare in the last year.
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
47.9M shares
92% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider bought Molina Healthcare stock and one insider sold. None of the 1 sale is marked on its filing as planned in advance.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
Richard C. Zoretic
Bought $100.1K on Feb 11 — 800 shares at $125.16, held through a trust or family, 9.1% of what they now own.
2 of 2 earlier purchases did better than the S&P 500
Big investors
People and funds that reported owning 5% or more of Molina Healthcare, newest first.
US Congress
Members of Congress who reported trading Molina Healthcare in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Molina Healthcare.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Feb 12BoughtRichard C. ZoreticFeb 12 · Traded Feb 11 · Director+9.1%via a trust or family800 @ $125.16$100.1K
Aug 8, 2025SoldRonna RomneyAug 8, 2025 · Traded Aug 6, 2025 · Directorvia a trust or family700 @ $153.74$107.6K
Aug 6, 2025BoughtJames WoysAug 6, 2025 · Traded Aug 4, 2025 · Chief Operating Officer+6.1%4,500 @ $156.36$703.6K
Aug 6, 2025BoughtJames WoysAug 6, 2025 · Traded Aug 4, 2025 · Chief Operating Officer+7.9%5,500 @ $155.59$855.7K
Analysts, earnings and news
Analysts' price target
$209.12 average
17 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q2 '26$1.51 a share+$0.11
Q1 '26$2.35 a share+$0.44
Q4 '25−$2.75 a share−$3.08
Q3 '25$1.84 a share−$2.05